Improve Outcomes for Older Allogeneic Transplant Recipients
Intervening on Frailty to Improve Outcomes for Older Allogeneic Transplant Recipients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jacqui Rick
- Phone Number: 2152209675
- Email: Jacqui.Rick@pennmedicine.upenn.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Penn Medicine
-
Contact:
- Jacqui Rick
- Phone Number: 215-220-9675
- Email: Jacqui.Rick@pennmedicine.upenn.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Cohort A (Prehab)
- Age 60 years or older.
- Planned allogeneic HCT in the next 1-6 months.
- Hematological malignancy as the indication for HCT.
- Pre-frail or frail by Fried frailty phenotype.
Cohort B (Rehab)
- Age 60 years or older.
- Planned allogeneic HCT or HCT within the last 30 days.
- Hematological malignancy as the indication for HCT.
Exclusion Criteria:
Cohorts A and B
1. Comorbid disability or illness that prevents safe exercise.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cohort A (Prehab)
Pre-frail and frail subjects will attend at least twice weekly exercise sessions with a physical therapist and be given an exercise program to complete at home prior to admission for HCT.
Patients enrolled in this cohort can continue on to Cohort B.
|
Pre-frail and frail potential HCT recipients 60 years and older will participate in a supervised exercise program from the time of enrollment up until HCT admission.
Exercise compliance will be measured in part through physical activity trackers.from
time of discharge from HCT until day +100 post-HCT.
All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT.
Exercise compliance will be measured in part through physical activity trackers.
|
|
Experimental: Cohort B (Rehab)
All patients 60 years and older upon discharge from their initial hospital stay for HCT will attend at least weekly exercise sessions with a physical therapist and be given an exercise program to complete at home with sessions continued through Day +100 after HCT.
|
All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT.
Exercise compliance will be measured in part through physical activity trackers.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of enrolled subjects who participate in the supervised exercise program
Time Frame: From 3 months prior to HCT to 100 days after HCT
|
From 3 months prior to HCT to 100 days after HCT
|
|
Median number of exercise sessions delivered pre-HCT and post-HCT.
Time Frame: From 3 months prior to HCT to 100 days after HCT
|
From 3 months prior to HCT to 100 days after HCT
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Hospital LOS for HCT
Time Frame: From date of randomization until the date of first documented discharge from the hospital, assessed up to 100 months
|
From date of randomization until the date of first documented discharge from the hospital, assessed up to 100 months
|
|
Rate of readmission
Time Frame: From time of discharge from initial hospital stay up through 1-2 years after HCT
|
From time of discharge from initial hospital stay up through 1-2 years after HCT
|
|
6-month and 1-year overall mortality
Time Frame: From day 0 of HCT to 6 months and 1-year] 6. 1-year and 2-year OS
|
From day 0 of HCT to 6 months and 1-year] 6. 1-year and 2-year OS
|
|
1-year and 2-year OS
Time Frame: From day 0 of HCT to 1-year and 2-years
|
From day 0 of HCT to 1-year and 2-years
|
|
1-year and 2-year PFS
Time Frame: From day 0 of HCT to 1-year and 2-years
|
From day 0 of HCT to 1-year and 2-years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Shannon McCurdy, MD, Penn Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- UPCC 07422
- Penn IRB# 851615 (Other Identifier: University of Pennsylvania IRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.